Skip to main content

Beckman Coulter Prices Notes Offering; Files for Common Stock Offering

NEW YORK (GenomeWeb News) – Beckman Coulter has priced two senior notes offerings and has filed a prospectus to sell up to $250 million worth of common stock, which will help pay for its $780 million acquisition of Olympus' diagnostics business.

The offerings were expected, as Beckman said in late February that it would pay for the acquisition through a combination of around $500 million worth of new debt and roughly $300 million of its common stock.

Today, Beckman said that it has priced $250 million worth of senior notes that mature in 2015 at a rate of 6 percent, and it priced $250 million worth of senior notes that mature in 2019 at a rate of 7 percent. The offerings are expected to close on May 21.

The firm also has filed a prospectus to raise $235 million, or $250 million if the underwriters exercise the over-allotment option, through the sale of common stock. The firm did not say when it expects to complete the common stock offering.

Beckman's purchase of the Olympus diagnostics business cleared US antitrust review by the Federal Trade Commission last week.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.